Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

Figures & data

Table 1 Baseline demographic, clinical characteristics, and treatment of 76 case patients and 55 controls observed over a 3-year period

	Psoriatic arthritis	Rheumatoid arthritis	P value
Patient N	76	55	NS
Females (N/%)	35 (46%)	40 (73%)	0.004
Males (N/%)	41 (54%)	15 (27%)
Age (years)	46 ± 10.2	50 ± 11.6	NS
Disease duration (months)	12 ± 8.3	16 ± 9.6	NS
Rheumatoid factor positive (N/%)	0	48 (89%)
Psoriatic arthritis pattern
Peripheral	45 (59%)
Axial	7 (9%)
Mixed	24 (31.5%)
Fatigue (VAS 0–100 mm)	58 ± 14.3	62 ± 14.9	NS
Pain (VAS 1–100)	66 ± 13.4	69 ± 10.8	NS
Articular morning stiffness (minutes)	120 ± 46.2	132 ± 55.3	NS
Tender joint count (N)	11 ± 4.1	12 ± 3.5	NS
Swollen joint count (N)	5 ± 2.1	7 ± 3.3	NS
Erythrocyte sedimentation rate (mm/h)	40 ± 15.2	46 ± 19.1	NS
C-reactive protein (mg/dL)	4.4 ± 1.9	4.9 ± 2.2	NS
Patients with dactylitis (N/%)	10 (13%)	0 (0%)	0.014
Patients with enthesitis/tenosynovitis (N/%)	22 (29%)	3 (5%)	0.002
Patients with extra-articular features (N/%)	8 (12%)	5 (9%)	NS
Disease activity score	5.21 ± 0.87	5.48 ± 0.34	NS
Bath Ankylosing	6.1 ± 1.1
Spondylitis Disease
Activity Index
Psoriatic Arthritis Severity	8.7 ± 5.9
Index score
Methotrexate (N/%)	64 (84%)	47 (85%)	NS

Notes: Bath Ankylosing Spondylitis Disease Activity Index was calculated in patients with axial and mixed pattern PsA (31 patients). Except where otherwise indicated, data are expressed as mean ± SD.

Abbreviations: N, number; NS, not significant; SD, standard deviation; VAS, visual analog scale.

Table 2 Frequency of remission in psoriatic arthritis (PsA) patients and rheumatoid arthritis (RA) controls receiving adalimumab (ADA), time to remission, and duration of remission after ADA dose reduction

	Psoriatic arthritis 76 patients	Rheumatoid arthritis 55 patients	P value
Overall remission (N/%)	53 (69.7%)	17 (30.9%)	0.019
Combined methotrexate (N/%)	46 (86.7%)	16/17 (94.1%)	NS
Remission by PsA pattern
• Peripheral	32 (71.1%)
• Axial	5 (71.4%)
• Mixed	16 (66.6%)
Time to remission (months/mean ± SD)	5.1 ± 1.2	6.3 ± 1.6	NS
PsA remission after ADA dose reduction (N/%)	47 (88.6%)	3 (17.6%)	0.016
Relapse by PsA pattern (N/%)
• Peripheral	3 (9.3%)
• Axial	1 (20%)
• Mixed	2 (12.5%)
Time to relapse (months/mean ± SD)	8.3 ± 3.4	7.2 ± 4.2	NS
Duration of follow-up (months/mean ± SD)	28.9 ± 8.4	24.2 ± 6.4	NS

Abbreviations: ADA, adalimumab; PsA, Psoriatic arthritis; N, number; NS, not significant; SD, standard deviation.